NOISESaved copy
Coverage history

Assembled by NOISE.

Saved report copy

Recorded

FDA approves daraxonrasib, extending survival for patients with advanced pancreatic cancer

The FDA approved Revolution Medicines’ daily pill daraxonrasib, sold as Rasonque, for advanced pancreatic cancer after prior treatment has failed. In a randomized, company-funded trial of 500 patients with metastatic disease, median survival was 13.2 months with daraxonrasib versus 6.7 months with chemotherapy, though side effects include digestive problems, rash and fatigue. NPR reported a one-month price of about $39,800 and expedited approval, while The Washington Post emphasized the pill’s more convenient administration and generally lower burden than IV chemotherapy.